HAG预激化疗作为诱导缓解方案治疗老年人急性髓系白血病和骨髓增生异常综合征的临床观察

Clinical observation of HAG regimen in remission inductive treatment for elderly patients with acute myeloid leukemia and myelodysplastic syndrome

目的观察HAG预激化疗作为诱导缓解方案在治疗老年急性髓系白血病（AML）和骨髓增生异常综合征-难治性贫血伴原始细胞增多型（MDS—RAEB）患者中的疗效。方法对应用HAG预激方案治疗的21例AML和9例MDS—RAEB患者（≥60岁）的临床资料进行回顾性总结，包括疾病完全缓解（CR）率、有效率以及不良反应。结果21例老年AML患者中，HAG诱导缓解的有效率为66．7％（14／21），其中CR率为47．6％（10／21）；9例老年MDS．RAEB患者中，CR率为55．6％（5／9）；HAG预激化疗的主要不良反应为因骨髓抑制继发的感染，调整化疗方案后所有患者均能耐受。结论HAG预激化疗作为诱导缓解方案适用于老年AML和MDS—RAEB患者。

Objective To observe the efficacy of HAG regimen in remission inductive treatment for elderly patients with acute myeloid leukemia （AML） and myelodysplastic syndrome-refractory anemia with excess blasts （MDS-RAEB）. Methods The clinical features of 21 cases with AML and 9 cases with MDS- RAEB （≥60 year old） treated with HA-G regimen in remission induction were retrospectively analyzed, including the complete remission （CR） rate, efficiency rate as well as their toxicities. Results In 21 elderly patients with AML treated with HAG regimen, the efficiency rate was 66.7 % （14/21）, CR rate 47.6 % （10/21）. In 9 elderly patients with MDS-RAEB, the CR rate was 55.6 % （5/9）. The main toxicity of HA-G regimen was infections secondary to hematopoiesis suppression after chemotherapy. All patients were well tolerated to adjusted regimen. Conclusion The HA-G regimen is much effective in remission induction for elderly patients with AML and MDS-RAEB.